TG Therapeutics, Inc. (0VGI.L)
USD 31.97
(-5.69%)
USD 31.97
(-5.69%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 17.86 Million USD | 192.82% |
| 2022 | -19.24 Million USD | 91.25% |
| 2021 | -219.84 Million USD | 57.02% |
| 2020 | -511.46 Million USD | -612.02% |
| 2019 | -71.83 Million USD | -71.48% |
| 2018 | -41.89 Million USD | 25.97% |
| 2017 | -56.59 Million USD | -126.7% |
| 2016 | -24.96 Million USD | 54.49% |
| 2015 | -54.84 Million USD | 1.06% |
| 2014 | -55.43 Million USD | -39.49% |
| 2013 | -39.74 Million USD | -198.84% |
| 2012 | -13.29 Million USD | -173.42% |
| 2011 | -4.86 Million USD | -126.53% |
| 2010 | 18.33 Million USD | 852.21% |
| 2009 | 1.92 Million USD | 66.93% |
| 2008 | 1.15 Million USD | 277.52% |
| 2007 | -649.68 Thousand USD | 78.55% |
| 2006 | -3.02 Million USD | 69.17% |
| 2005 | -9.82 Million USD | -985.0% |
| 2004 | -905.65 Thousand USD | 87.78% |
| 2003 | -7.41 Million USD | -1184.35% |
| 2002 | 683.7 Thousand USD | 142.95% |
| 2001 | -1.59 Million USD | 40.24% |
| 2000 | -2.66 Million USD | 23.9% |
| 1999 | -3.5 Million USD | 39.66% |
| 1998 | -5.8 Million USD | 31.76% |
| 1997 | -8.5 Million USD | -269.57% |
| 1996 | -2.3 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 29.62 Million USD | -18.14% |
| 2024 Q1 | 36.19 Million USD | 102.62% |
| 2023 Q3 | -218.15 Million USD | -154.58% |
| 2023 Q2 | -85.69 Million USD | -71.92% |
| 2023 FY | 17.86 Million USD | 192.82% |
| 2023 Q4 | 17.86 Million USD | 108.19% |
| 2023 Q1 | -49.84 Million USD | -159.01% |
| 2022 FY | -19.24 Million USD | 91.25% |
| 2022 Q4 | -19.24 Million USD | 30.34% |
| 2022 Q1 | -106.61 Million USD | 51.5% |
| 2022 Q2 | -66.66 Million USD | 37.47% |
| 2022 Q3 | -27.62 Million USD | 58.57% |
| 2021 Q2 | -366.86 Million USD | 14.58% |
| 2021 Q3 | -299.02 Million USD | 18.49% |
| 2021 Q4 | -219.84 Million USD | 26.48% |
| 2021 FY | -219.84 Million USD | 57.02% |
| 2021 Q1 | -429.5 Million USD | 16.02% |
| 2020 Q3 | -213.07 Million USD | 2.92% |
| 2020 Q4 | -511.46 Million USD | -140.04% |
| 2020 FY | -511.46 Million USD | -612.02% |
| 2020 Q2 | -219.48 Million USD | -1879.31% |
| 2020 Q1 | -11.08 Million USD | 84.56% |
| 2019 Q1 | -26.62 Million USD | 36.45% |
| 2019 Q4 | -71.83 Million USD | -1284.33% |
| 2019 Q3 | -5.18 Million USD | 73.21% |
| 2019 Q2 | -19.37 Million USD | 27.24% |
| 2019 FY | -71.83 Million USD | -71.48% |
| 2018 Q1 | -82.67 Million USD | -46.09% |
| 2018 FY | -41.89 Million USD | 25.97% |
| 2018 Q4 | -41.89 Million USD | 40.69% |
| 2018 Q3 | -70.62 Million USD | 33.03% |
| 2018 Q2 | -105.46 Million USD | -27.57% |
| 2017 Q3 | -91.66 Million USD | -18.35% |
| 2017 Q2 | -77.44 Million USD | 18.87% |
| 2017 Q1 | -95.46 Million USD | -282.43% |
| 2017 Q4 | -56.59 Million USD | 38.26% |
| 2017 FY | -56.59 Million USD | -126.7% |
| 2016 Q4 | -24.96 Million USD | 14.04% |
| 2016 Q3 | -29.03 Million USD | -1.94% |
| 2016 Q2 | -28.48 Million USD | 21.58% |
| 2016 Q1 | -36.32 Million USD | 33.77% |
| 2016 FY | -24.96 Million USD | 54.49% |
| 2015 Q4 | -54.84 Million USD | 15.98% |
| 2015 FY | -54.84 Million USD | 1.06% |
| 2015 Q1 | -85.73 Million USD | -54.64% |
| 2015 Q2 | -60 Million USD | 30.01% |
| 2015 Q3 | -65.28 Million USD | -8.79% |
| 2014 Q2 | -36.91 Million USD | 25.39% |
| 2014 Q1 | -49.48 Million USD | -24.5% |
| 2014 Q4 | -55.43 Million USD | -4.52% |
| 2014 FY | -55.43 Million USD | -39.49% |
| 2014 Q3 | -53.04 Million USD | -43.67% |
| 2013 Q3 | -47.23 Million USD | -355.32% |
| 2013 FY | -39.74 Million USD | -198.84% |
| 2013 Q4 | -39.74 Million USD | 15.86% |
| 2013 Q2 | -10.37 Million USD | 14.16% |
| 2013 Q1 | -12.08 Million USD | 9.12% |
| 2012 FY | -13.29 Million USD | -173.42% |
| 2012 Q1 | -15.58 Million USD | -220.34% |
| 2012 Q3 | -12.31 Million USD | 19.47% |
| 2012 Q2 | -15.29 Million USD | 1.84% |
| 2012 Q4 | -13.29 Million USD | -7.99% |
| 2011 Q3 | 17.39 Million USD | 2.25% |
| 2011 Q4 | -4.86 Million USD | -127.97% |
| 2011 Q1 | 18.32 Million USD | -0.05% |
| 2011 Q2 | 17.01 Million USD | -7.16% |
| 2011 FY | -4.86 Million USD | -126.53% |
| 2010 Q1 | 16.41 Million USD | 752.79% |
| 2010 FY | 18.33 Million USD | 852.21% |
| 2010 Q4 | 18.33 Million USD | 4.32% |
| 2010 Q3 | 17.57 Million USD | 3.75% |
| 2010 Q2 | 16.93 Million USD | 3.17% |
| 2009 Q3 | 1.62 Million USD | 15.66% |
| 2009 Q1 | 1.39 Million USD | 20.7% |
| 2009 Q4 | 1.92 Million USD | 18.43% |
| 2009 Q2 | 1.4 Million USD | 0.97% |
| 2009 FY | 1.92 Million USD | 66.93% |
| 2008 Q3 | 34.33 Thousand USD | 105.96% |
| 2008 FY | 1.15 Million USD | 277.52% |
| 2008 Q1 | -1.13 Million USD | -74.41% |
| 2008 Q2 | -576.35 Thousand USD | 49.14% |
| 2008 Q4 | 1.15 Million USD | 3258.93% |
| 2007 Q1 | -8.68 Million USD | -186.88% |
| 2007 FY | -649.68 Thousand USD | 78.55% |
| 2007 Q3 | -2.03 Million USD | 57.57% |
| 2007 Q4 | -649.68 Thousand USD | 68.04% |
| 2007 Q2 | -4.79 Million USD | 44.87% |
| 2006 Q4 | -3.02 Million USD | 22.58% |
| 2006 FY | -3.02 Million USD | 69.17% |
| 2006 Q3 | -3.91 Million USD | 35.28% |
| 2006 Q2 | -6.04 Million USD | 29.15% |
| 2006 Q1 | -8.53 Million USD | 13.17% |
| 2005 Q3 | -11.86 Million USD | -1998.92% |
| 2005 FY | -9.82 Million USD | -985.0% |
| 2005 Q1 | -544.95 Thousand USD | 39.83% |
| 2005 Q2 | -565.47 Thousand USD | -3.77% |
| 2005 Q4 | -9.82 Million USD | 17.21% |
| 2004 Q3 | -7.4 Million USD | 16.43% |
| 2004 Q4 | -905.65 Thousand USD | 87.78% |
| 2004 Q2 | -8.86 Million USD | 7.1% |
| 2004 Q1 | -9.54 Million USD | -28.72% |
| 2004 FY | -905.65 Thousand USD | 87.78% |
| 2003 Q3 | -32.11 Thousand USD | 92.13% |
| 2003 Q2 | -407.86 Thousand USD | 62.12% |
| 2003 Q1 | -1.07 Million USD | -257.46% |
| 2003 FY | -7.41 Million USD | -1184.35% |
| 2003 Q4 | -7.41 Million USD | -22985.89% |
| 2002 Q2 | -445.37 Thousand USD | 52.28% |
| 2002 Q3 | -375.84 Thousand USD | 15.61% |
| 2002 FY | 683.7 Thousand USD | 142.95% |
| 2002 Q4 | 683.7 Thousand USD | 281.91% |
| 2002 Q1 | -933.22 Thousand USD | 41.37% |
| 2001 Q4 | -1.59 Million USD | -261.31% |
| 2001 Q1 | -2.58 Million USD | 3.08% |
| 2001 Q2 | -1.03 Million USD | 60.09% |
| 2001 Q3 | -440.55 Thousand USD | 57.24% |
| 2001 FY | -1.59 Million USD | 40.24% |
| 2000 Q3 | -1.7 Million USD | -5.88% |
| 2000 Q1 | -3.11 Million USD | 11.01% |
| 2000 Q2 | -1.6 Million USD | 48.44% |
| 2000 Q4 | -2.66 Million USD | -56.65% |
| 2000 FY | -2.66 Million USD | 23.9% |
| 1999 Q2 | -4.1 Million USD | 18.0% |
| 1999 Q3 | -3.7 Million USD | 9.76% |
| 1999 Q4 | -3.5 Million USD | 5.41% |
| 1999 FY | -3.5 Million USD | 39.66% |
| 1999 Q1 | -5 Million USD | 13.79% |
| 1998 Q3 | -7 Million USD | 15.66% |
| 1998 FY | -5.8 Million USD | 31.76% |
| 1998 Q4 | -5.8 Million USD | 17.14% |
| 1998 Q1 | -7 Million USD | 17.65% |
| 1998 Q2 | -8.3 Million USD | -18.57% |
| 1997 Q4 | -8.5 Million USD | 14.14% |
| 1997 Q1 | -1.4 Million USD | 39.13% |
| 1997 FY | -8.5 Million USD | -269.57% |
| 1997 Q2 | -2.3 Million USD | -64.29% |
| 1997 Q3 | -9.9 Million USD | -330.43% |
| 1996 Q3 | -3.2 Million USD | -14.29% |
| 1996 Q4 | -2.3 Million USD | 28.13% |
| 1996 FY | -2.3 Million USD | 0.0% |
| 1996 Q2 | -2.8 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 117.35% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 157.219% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 90.982% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 43.98% |
| bluebird bio, Inc. | 108.57 Million USD | 83.548% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 298.114% |
| Imunon, Inc. | -4.69 Million USD | 480.101% |
| Editas Medicine, Inc. | -87.11 Million USD | 120.504% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.861% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 99.149% |
| Myriad Genetics, Inc. | 88.1 Million USD | 79.725% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 89.926% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 153.276% |
| Verastem, Inc. | -37.27 Million USD | 147.916% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.783% |
| Waters Corporation | 1.96 Billion USD | 99.089% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.933% |
| Biogen Inc. | 6.28 Billion USD | 99.716% |
| Nektar Therapeutics | 210.24 Million USD | 91.504% |
| Perrigo Company plc | 3.32 Billion USD | 99.462% |
| Dynavax Technologies Corporation | 106.63 Million USD | 83.249% |
| Illumina, Inc. | 1.21 Billion USD | 98.529% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -156.34% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 115.684% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 87.688% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -148.532% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 95.284% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 351.577% |
| Evolus, Inc. | 63.7 Million USD | 71.963% |
| Adicet Bio, Inc. | -142 Million USD | 112.578% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 148.533% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 165.911% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 96.106% |
| FibroGen, Inc. | 56.76 Million USD | 68.535% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 98.44% |
| OPKO Health, Inc. | 230.68 Million USD | 92.257% |
| Homology Medicines, Inc. | 18.43 Million USD | 3.119% |
| Geron Corporation | 14.76 Million USD | -21.008% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 98.873% |
| Exelixis, Inc. | -73.05 Million USD | 124.452% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 132.922% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 111.827% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 116.034% |
| Zoetis Inc. | 4.76 Billion USD | 99.625% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 108.939% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 277.361% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.187% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 222.578% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 98.306% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 98.155% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 113.192% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 98.706% |
| Blueprint Medicines Corporation | 702.83 Million USD | 97.459% |
| Insmed Incorporated | 721.62 Million USD | 97.525% |
| Incyte Corporation | -3.17 Billion USD | 100.563% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 97.668% |